Imbria Pharmaceuticals
Manufacturing · Massachusetts, United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
265 Franklin St Ste 1702, Boston, Massac...Phone Number
(617) 675-4060Website
www.imbria.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
1
1
1
1
1
1
About Imbria Pharmaceuticals
Imbria is a clinical-stage company focused on developing innovative therapies that enhance cellular energy to treat cardiometabolic disorders, particularly cardiovascular issues. Their pipeline includes treatments for conditions such as non-obstructive hypertrophic cardiomyopathy, stable angina, and heart failure with preserved ejection fraction. The company is dedicated to translating cellular metabolism insights into effective medicines for patients who currently face limited treatment options. Imbria aims to improve patients' lives by advancing new therapies that address significant cardiometabolic health challenges.Explore more
Imbria Pharmaceuticals Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Imbria Pharmaceuticals your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Imbria Pharmaceuticals, which may be a good buyer, showed buying intent in Masked Content Topic
Funding: Get notified immidiatlly once Imbria Pharmaceuticals has new funding data
Earning: See what the market has to say on Imbria Pharmaceuticals recently announced quarterly report
Check if Imbria Pharmaceuticals has recently received funding, and reach out quickly before it becomes old news!
Check out if Imbria Pharmaceuticals is spiking on competitors!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Congratulate Masked Content for being promoted to Masked Content at Imbria Pharmaceuticals
Click to see if Imbria Pharmaceuticals had a recent Job posting/layoffs
Website visits: Recent activity has been detected on your website
Product Launch: Get notified when Imbria Pharmaceuticals launches new products
Recommended Actions
Reach out to Masked Content who joined Imbria Pharmaceuticals as Masked Content
Find 2 more new buyers
Compare Similar Companies to Imbria Pharmaceuticals
Compare insights from companies similar to Imbria Pharmaceuticals, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Imbria Pharmaceuticals is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Imbria Pharmaceuticals is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Imbria Pharmaceuticals.
Imbria Pharmaceuticals financials insights
Gather financial insights about Imbria Pharmaceuticals, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2025
Series B
$57.5M
Imbria Pharmaceuticals Tech Stack
A closer look at the technologies used by Imbria Pharmaceuticals
Most Recent Scoops
Project
Laboratory Operations, Medical Research, Clinical Operations
Project
Laboratory Operations, Medical Research, Clinical Operations
Project
Product Development, Product Management, Medical Research, Pharmaceuticals, Clinical Operations
Executive Move
Executive Moves, Board of Directors
Lateral Move
Executive Move
Executive Moves, Lateral Move
Imbria Pharmaceuticals News & Media
Imbria Pharmaceuticals Receives FDA Orphan Drug Designation for Ninerafaxstat for Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy
BOSTON, June 24, 2026 (GLOBE NEWSWIRE) -- Imbria Pharmaceuticals, Inc. (Imbria), a clinical-stage company developing innovative therapeutics for cardiovascular diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to ninerafaxstat for the treatment of symptomatic non-obstructive hypertrophic cardiomyopathy (nHCM).Imbria Pharmaceuticals Receives FDA Orphan Drug Designation for Ninerafaxstat for Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy
BOSTON, June 24, 2026 (GLOBE NEWSWIRE) -- Imbria Pharmaceuticals, Inc. (Imbria), a clinical-stage company developing innovative therapeutics for cardiovascular diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to ninerafaxstat for the treatment of symptomatic non-obstructive hypertrophic cardiomyopathy (nHCM).Imbria Pharmaceuticals Announces Publication of IMPROVE-DiCE Phase 2a Data in Circulation, Demonstrating Ninerafaxstat as a Potential First-in-Class Therapy Targeting Cardiac Energetics in Cardiometabolic Disease
Data provide first human validation of cardiac energetics modulation as a therapeutic target in cardiometabolic heart disease, including heart failure with preserved ejection fraction (HFpEF)Imbria Pharmaceuticals Announces Extension of Series B Financing to Advance Ninerafaxstat for Cardiovascular Diseases
Imbria extends Series B financing with new investor AXA IM Alts to advance ninerafaxstat and address urgent global cardiovascular health challenges.
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Imbria Pharmaceuticals
Sign Up For FreeTo access detailed company insights
Imbria is a clinical-stage company focused on developing innovative therapies that enhance cellular energy to treat cardiometabolic disorders, particularly cardiovascular issues. Their pipeline includes treatments for conditions such as non-obstructive hypertrophic cardiomyopathy, stable angina, and heart failure with preserved ejection fraction. T... Read More
